CorMedix Inc. Announces Commercial And Operational Updates Related To Its Business And Anticipated Launch Of DefenCath
Portfolio Pulse from Benzinga Newsdesk
CorMedix Inc. (NASDAQ:CRMD) has announced updates on the commercial launch of DefenCath, including a submitted HCPCS application for a J-Code to CMS, ongoing discussions for Medicare Part B reimbursement, and interest from health systems. The inpatient launch is expected by April 15, 2024, and outpatient availability is anticipated no sooner than July 1, 2024, pending CMS decisions. CorMedix may set an initial list price for DefenCath before CMS's final determination, with plans to adjust it based on the outcome. The company has sufficient funds for the launch and is expanding its staff in preparation.
January 08, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CorMedix is preparing for the launch of DefenCath with a J-Code application submitted to CMS, discussions for Medicare Part B reimbursement, and confirmed interest from health systems. The company is funded for the launch and is expanding its commercial team.
The news indicates positive developments for CorMedix, including progress with CMS for DefenCath reimbursement and confirmed interest from health systems, which are likely to be viewed favorably by investors. The company's preparedness for the launch with sufficient funding and staff expansion further supports a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100